In summary, the cross-validation results are consistent with the model building data AUCs and show that a panel of multiple markers performed better than the current most used marker, serum AFP (sensitivity: 48.2%; specificity: 99%), for detecting HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.